An interventional study of Contact Lenses in Myopia, sponsored by Menicon Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-06.
Sponsored by Menicon Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 222 studies in Myopia with a site in China — 80 open to participants now, 102 under way, 4 of them phase 3. Myopia · China.
Among the 222 studies in Myopia with a site in China, this one is the 79th largest by enrollment of the 155 interventional ones that give a count, is one of 13 that started in 2018, is one of 136 with no phase, and was the 48th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →80 of the 222 studies in Myopia with a site in China are open now. Recruiting first, the newest first:
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
Beijing Tongren Hospital · Sites in China
Healthy volunteers
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 6–18 · Healthy volunteers
CooperVision International Limited (CVIL) · Sites in China
Ages 8–10
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
222 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 8 · Phase 4 7
First in 2005; this study’s year is marked. 13 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 150 across the 155 interventional studies, 1,000 across the 67 observational. Of the 77 that completed or were terminated, 5 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 222 have an industry lead sponsor. The 10 most frequent:
Menicon Co., Ltd. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Menicon Co., Ltd. has 4 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
35 of the studies in Myopia with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT07585877Zhongda HospitalEffect of Branched-Chain Amino Acid Supplementation on Myopia Progression | 2026-12-30 |
| NCT07119723Tianjin Medical University Eye HospitalEnvironmental Factors and Myopia Prevalence Among Uyghur Students in Remote China | 2026-12-30 |
| NCT07008001SightGlass Vision, Inc.Assessment of DOT Spectacles in Chinese Children Extension | 2026-12-31 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
Add all 35 to your calendar (.ics) → With an account.
Among the 222 studies in Myopia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project is a multi-center, randomized, parallel-controlled, non-inferior clinical trial of soft contact lenses.
The test product is the Soft Contact Lens (model: Spherical Lens), and the control product is a commercially available soft contact lens (model: SiHy Daily). The number of enrolled subjects is 148, and clinical observation is performed for 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Both eyes are ametropia, and there is no case where the investigator believes that the soft contact lens cannot be worn;
: The case of wearing a soft contact lens as referred to in this trial is: i) No eyelid abnormalities or infections; ii) No slit lamp findings iii) No other active eye diseases.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized to Spherical Lens worn in a daily disposable mode
Device: Contact Lenses
Randomized to SiHy Daily worn in a daily disposable mode
Device: Contact Lenses
Contact lenses for vision correction
The ratio of corrected visual acuity of left and right eyes is ≥5.0
The standard logarithmic visual acuity chart consistent with the guiding principle is adopted in this scheme. - Success criteria: If the lower limit of 95% CI of the evaluated rate of corrected for visual acuity for both eyes ≥ 5.0 at 1 week visit is ≥-10%, the primary endpoint of the two groups is non-inferior.
Time frame: 1 week
The occurrence of adverse events
Compare the number of adverse events and serious adverse events, the number of cases and the incidence rate; list the number and cases of adverse events; describe the adverse events that are related to the investigational products.
Time frame: 3 month
BCVA (spectacles) and BCVA (CL)
BCVA (spectacles and CL) of both eyes are compared at baseline and at each follow-up.
Time frame: 1 week, 1 month, 3 months
Ran from Nov 2018 to primary completion in May 2019, 5 months.
Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 5 months is below that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Menicon Co., Ltd.